Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Myllia Biotechnology
Vienna, Vienna, Austria
- Ownership
- Private
- Employees
- ~30
- Development stage
- Other
01
Overview
Myllia enables high-throughput, single-cell CRISPR-based functional genomics and target discovery; platforms validated in collaboration with leading partners (e.g., Boehringer Ingelheim, GSK, Ultima Genomics). No clinical trials or therapeutic agents; technology under active deployment.
- Therapeutic areas
- OncologyInfectious DiseasesImmunology
- Modalities
- CRISPR-based screeningFunctional genomicsGuide RNA therapy
- Industry
- Drug Discovery Services
02
Partnerships
GSK (drug target discovery in immune cells)Boehringer Ingelheim (joint research in cancer cell lines)Ultima Genomics (sequencing technology partnership)
Beyond the preview
Go deeper on Myllia Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myllia Biotechnology.